| Autor: |
Tomas-Grau RH; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Maldonado-Galdeano C; Centro de Referencia para Lactobacilos - CERELA (CONICET), Tucumán 4000, Argentina., López MA; Public Healthcare Administration (SIPROSA), Tucumán 4000, Argentina., Pingitore EV; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Aznar P; Néstor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA), Tucumán 4000, Argentina., Alcorta ME; Néstor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA), Tucumán 4000, Argentina., Del Mar Vélez EM; Néstor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA), Tucumán 4000, Argentina., Stagnetto A; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Soliz-Santander SE; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Ávila CL; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Socias SB; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Costas D; Néstor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA), Tucumán 4000, Argentina., Chahla RE; Public Healthcare Administration (SIPROSA), Tucumán 4000, Argentina., Perdigón G; Centro de Referencia para Lactobacilos - CERELA (CONICET), Tucumán 4000, Argentina., Chehín RN; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Ploper D; Instituto de Investigación en Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA), Tucumán 4000, Argentina., Cazorla SI; Centro de Referencia para Lactobacilos - CERELA (CONICET), Tucumán 4000, Argentina. |
| Abstrakt: |
The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70-96 years old), evolution of the humoral immune response over time to Gam-COVID-Vac (Sputnik V), a vaccine based on heterologous recombinant adenovirus-26 (Ad26) and adenovirus-5 (Ad5) carrying the Spike genome, was analyzed by an anti-RBD ELISA. At 28 days post vaccination (dpv), a seroconversion rate of 91% was achieved, showing the importance of administering at least two doses of Gam-COVID-Vac to elicit a robust immune response, especially in elderly individuals without previous SARS-CoV-2 infection. Interestingly, IgG specific antibodies that reached their highest titers around 28 dpv (median = 740), persisted without significant decrease after 60 dpv (median = 650). After 90 dpv, IgG titers began to drop, and at 180 dpv only 44.7% of the elderly individuals remained with detectable anti-RBD IgG antibodies. No significant differences were observed in specific humoral immune responses between genders at early times point. However, at 60 dpv anti-RBD titers were more persistent in elderly females, and only dropped at 90 dpv ( p < 0.0001). As expected, the highest antibodies titers were elicited in the youngest subgroup (70-74 years). Our results show that Gam-COVID-Vac was able to deal with the ageing of the immune system, eliciting a robust immune response in an elderly cohort, which lasted approximately 90 dpv at high levels, and protected against COVID-19. |
